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Abstract
Cohort-based enrollment can slow down dose-finding trials since the outcomes of the
previous cohort must be fully evaluated before the next cohort can be enrolled. This results
in frequent suspension of patient enrollment. The issue is exacerbated in recent immune
oncology trials where toxicity outcomes can take a long time to observe. We propose a novel
phase I design, the probability-of-decision toxicity probability interval (PoD-TPI) design,
to accelerate phase I trials. PoD-TPI enables dose assignment in real time in the presence
of pending toxicity outcomes. With uncertain outcomes, the dose assignment decisions are
treated as a random variable, and we calculate the posterior distribution of the decisions.
The posterior distribution reflects the variability in the pending outcomes and allows a direct
and intuitive evaluation of the confidence of all possible decisions. Optimal decisions are
calculated based on 0-1 loss, and extra safety rules are constructed to enforce sufficient
protection from exposing patients to risky doses. A new and useful feature of PoD-TPI
is that it allows investigators and regulators to balance the trade-off between enrollment
speed and making risky decisions by tuning a pair of intuitive design parameters. Through
numerical studies, we evaluate the operating characteristics of PoD-TPI and demonstrate
that PoD-TPI shortens trial duration and maintains trial safety and efficiency compared to
existing time-to-event designs.
Keywords: Clinical trial design; Decision theory; Dose finding; Late-onset toxicity; Maximum
tolerated dose
1 Introduction
Phase I clinical trials in oncology aim to find the maximum tolerated dose (MTD) of a new drug.
The MTD is defined as the highest dose with a dose limiting toxicity (DLT) probability close to or
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lower than a pre-specified target level pT. Many phase I dose-finding designs like the 3+3 design
(Storer, 1989) and the continual reassessment method (CRM, O’Quigley et al., 1990) have been
proposed for this purpose, along with the goal of maximizing the chance of treating patients at
safe and efficacious doses. In practice, usually a set of candidate dose levels (from low to high)
{1, . . . , D} is pre-specified, and both the toxicity and the efficacy of the drug are assumed to
monotonically increase with dose level. Let pd denote the true and unknown DLT probability of
dose d, p1 ≤ · · · ≤ pD. The value of pd is estimated according to the DLT outcomes of the treated
patients, and the selection of the MTD is based on the estimate of pd.
In practical trials, due to limited sample size, the DLT probability pd is estimated with un-
certainty. To account for the uncertainty, a class of interval-based dose-finding designs has been
proposed. Cheung and Chappell (2002) introduced the idea of indifference interval, where any
dose with pd ∈ [pT − , pT + ] can be treated as an estimated MTD for a small value . Later, Ji
et al. (2007) proposed a phase I design that solely depends on properties of toxicity probability
intervals (TPI), known as the TPI design. The TPI design was further extended and polished by
Ji et al. (2010), Ji and Wang (2013) and Guo et al. (2017), leading to the modified TPI (mTPI)
and mTPI-2 designs. Simpler model-assisted designs like the cumulative cohort design (CCD,
Ivanova et al., 2007) and the Bayesian optimal interval design (BOIN, Liu and Yuan, 2015) also
uses intervals as the basis for decision making. The latest i3+3 design (Liu et al., 2019) is again
based on interval rules, but without a model.
The last decade has seen a growth of the use of immunotherapies for treating cancer. The
toxicities of immunotherapies can be late-onset (Kanjanapan et al., 2019), meaning it can take
longer time to observe than traditional cytotoxic cancer therapies. This presents some challenges
to traditional phase I designs like the mTPI-2, as these designs can only make dose decisions when
all the previous DLT outcomes are ascertained. In other words, if some patients are still being
followed within their assessment windows, patient accrual has to be suspended while waiting for the
previous outcomes, resulting in waste of precious patient resources and prolonged trial duration.
As a result, there is a need of novel designs that can shorten the duration of phase I trials. Several
phase I designs have been proposed to allow dose decisions in the presence of incomplete DLT
outcomes. These include the time-to-event continual reassessment method (TITE-CRM, Cheung
and Chappell, 2000), rolling six design (Skolnik et al., 2008), time-to-event Bayesian optimal
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interval design (TITE-BOIN, Yuan et al., 2018), time-to-event keyboard design (TITE-keyboard,
Lin and Yuan, 2018) and rolling TPI design (R-TPI, Guo et al., 2019). Safety of these designs have
not been fully explored and is often a concern in practice. For example, what is the risk of making
a wrong escalation decision when not all the toxicity outcomes have been observed from existing
patients in the trial? Questions like this need to be carefully addressed to help investigators and
regulators understand the impact of reduction in trial duration.
In this paper, we propose the probability-of-decision toxicity probability interval (PoD-TPI)
design to accelerate phase I trials. We calculate the posterior distribution of the number of DLTs
among the pending outcomes, with which we then infer the posterior probability of possible dose-
finding decisions. Importantly, the posterior distribution of decisions enables a direct and intuitive
evaluation of the confidence of the possible decisions, which can be used to assess the risk of any
decision rules based on the posterior distribution. The decision with the highest PoD is the optimal
decision to make. When the PoD of the optimal decision is high enough, or the optimal decision
is not risky (e.g., de-escalation), the decision may be executed without waiting for the pending
outcomes. On the other hand, if the PoD of the optimal decision is not high enough, and the
optimal decision is risky (e.g., escalation), the sensible decision is to suspend the enrollment and
wait for some more outcomes to be observed before making a decision. Through these reasoning,
the proposed PoD-TPI design quantifies the risk of making aggressive decisions and present them
via simulation studies. Adopting to an optimal and conservative decision framework and balancing
the need to shorten trial duration and protect patient safety, the PoD-TPI design might be a new
and useful method for practical trials.
The idea of PoD-TPI is different from existing TITE designs. In TITE-CRM, TITE-BOIN and
TITE-keyboard, the follow-up times of the pending patients are incorporated in the likelihood of
the DLT probabilities. Interest lies in the estimation of pd, and the dose decision is deterministic
based on pd. In contrast, in PoD-TPI, the follow-up times are used to estimate the probability of
a pending patient experiencing DLT in the future. Interest now lies in the posterior distribution of
the random number of DLTs if all patients were fully followed, and the dose decision is treated as a
random variable. The idea of PoD-TPI is also different from the R-TPI design. The R-TPI consists
of fixed decision rules that accommodate pending outcomes. To ensure safety, dose escalation is
only allowed when the mTPI-2 decision is still escalation even if all pending outcomes are DLTs.
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However, R-TPI does not make use of the follow-up times thus is less efficient. In addition to
the modeling and application of PoDs, PoD-TPI has two other unique features: (1) the use of
probability cutoffs to calibrate the risks to patients, and (2) the proposed risk as a metric for
assessing the operating characteristics of designs that do not use complete data. These features
will be more clear in the following discussion.
The rest of the paper is organized as follows. In Section 2, we review the mTPI-2 design, upon
which the PoD-TPI design is built. In Section 3, we propose the PoD-TPI design based on a
probability model for the time to DLT, which is developed in Section 4. In Section 5, we illustrate
the PoD-TPI design through two hypothetical trial examples. In Section 6, we conduct extensive
simulation studies to evaluate the operating characteristics of the PoD-TPI design. In Section 7,
we conclude with a discussion.
2 Review of mTPI-2
We first give a brief review of the mTPI-2 design (Guo et al., 2017), upon which the PoD-TPI
design is anchored. Under the mTPI-2 design, patients are usually enrolled in cohorts, and the first
cohort is treated at the lowest dose. At a certain moment in the trial, suppose dose d is currently
used to treat patients, and denote by pd ∈ [0, 1] its true (and unknown) DLT probability. After the
toxicity outcomes of the previous cohort are observed, physicians need to make a decision A for
the treatment of the next cohort. Here A ∈ {−1, 0, 1}, corresponding to a decision of de-escalation
(−1) to the next lower dose, stay (0) at the current dose, or escalation (1) to the next higher dose,
respectively. Accordingly, the dose (d+A) will be used to treat the next cohort, subject to some
additional safety rules. In the case that d is the lowest dose and A = −1, or d is the highest dose
and A = 1, the dose d will be kept for the next cohort, i.e., A = 0.
In mTPI-2, the dose decision A is based on posterior inference of pd. Suppose a total of N
patients have been treated. We use Yi and Zi to denote the DLT outcome and dose assignment
of patient i, where Yi = 1 (or 0) indicates a DLT (or non-DLT) outcome, and Zi ∈ {1, . . . , D},
i = 1, . . . , N . Here, a DLT outcome means the patient experiences DLT within some assessment
window. If the patient does not experience DLT during the time window, we declare that the
4
patient has no DLT. The DLT outcome is modeled by a Bernoulli distribution,
Yi | Zi = d ∼ Bernoulli(pd).
Let nd represent the number of patients who have experienced DLT at dose d, and let md denote
those who have not. That is, nd =
∑N
i=1 1(Yi = 1, Zi = d) and md =
∑N
i=1 1(Yi = 0, Zi = d). The
likelihood of pd is
L(pd | nd,md) = pndd (1− pd)md . (1)
Suppose the (N+1)-th patient is just enrolled and the DLT outcomes for the previous patients
are fully observed. To make a proper dose assignment for the new patient, mTPI-2 considers a
partition of the parameter space of pd, the [0, 1] interval, into the following three intervals,
IE = [pT − 1, pT + 2] (equivalence interval),
IU = [0, pT − 1) (underdosing interval),
IO = (pT + 2, 1] (overdosing interval).
The values 1 and 2 are elicited by physicians, such that the doses within IE are considered so
close to the MTD that the physicians would agree to select them as the estimated MTD. The
lengths of the three intervals IE, IU and IO are different. To avoid undesirable decisions due
to the effect of Ockham’s razor (Jefferys and Berger, 1992), the intervals IU and IO are further
divided into subintervals {IU1 , . . . , IUK1} and {IO1 , . . . , IOK2}. The subintervals have an equal
length of (1 + 2), except those reaching the boundary of [0, 1]. For example, when pT = 0.3
and 1 = 2 = 0.05, the equivalence interval is IE = [0.25, 0.35]. The underdosing interval is
divided into K1 = 3 subintervals, IU1 = [0.15, 0.25), IU2 = [0.05, 0.15) and IU3 = [0, 0.05), and
the overdosing interval is divided into K2 = 7 subintervals, IO1 = (0.35, 0.45], IO2 = (0.45, 0.55],
IO3 = (0.55, 0.65], IO4 = (0.65, 0.75], IO5 = (0.75, 0.85], IO6 = (0.85, 0.95] and IO7 = (0.95, 1].
Finally, mTPI-2 casts the dose-finding decision as a model selection problem under a decision
theoretic framework. Let model Md = j ∈ {U1, . . ., UK1 , E, O1, . . ., OK2} be an indicator
of pd ∈ Ij. Each candidate model is assigned a prior probability, and a prior distribution is
constructed for pd given Md being the true model. Specifically,
Pr(Md = j) = 1/(K1 +K2 + 1), for j = U1, . . . ,UK1 ,E,O1, . . . ,OK2 ;
pd | Md ∼ TBeta(1, 1; IMd),
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where TBeta(·, ·; I) represents a truncated beta distribution restricted to interval I. Let M∗ =
arg maxj Pr(Md = j | nd,md). The decision rule of mTPI-2 is given by
A =

0, if M∗ = E;
1, if M∗ ∈ {U1, . . . ,UK1};
−1, if M∗ ∈ {O1, . . . ,OK2};
It is shown in Guo et al. (2017) that the decision rule is optimal in the sense that it minimizes
the posterior expected loss under a 0-1 loss.
Suppose pT, 1 and 2 are given and fixed. The decision A only depends on the values of nd
and md. As a result, we can write A = A(nd,md) : N×N→ {−1, 0, 1} as a deterministic function
of nd and md. For example, with pT = 0.30 and 1 = 2 = 0.05, we have A(0, 3) = 1, A(1, 2) = 0,
A(2, 1) = −1 and A(3, 0) = −1. The notation of A(nd,md) will be used in the PoD-TPI design
next.
3 The PoD-TPI Design
As noted in Section 1, a potential limitation of the mTPI-2 design (and many other cohort-based
phase I designs) is that the toxicity outcomes for the previous cohorts must be fully observed
before a dose decision can be made for the next cohort. While waiting for the DLT assessment
of the previous patients, patient accrual needs to be suspended and eligible patients have to be
turned away. Such trial suspension is undesirable in practice. The PoD-TPI design is motivated
by the need to reduce the frequency of enrollment suspension but at the same time maintain safety.
Under the PoD-TPI design, patients are enrolled in cohorts, say, of size 3. The first cohort of
patients is treated at the starting dose level, denoted by d0. In most cases, d0 is chosen as the
lowest dose level, d0 = 1.
At a given moment of the trial, suppose a total of N patients have been treated, the current
dose is d, and the (N + 1)-th patient is available for enrollment. Recall that Yi and Zi denote
the DLT outcome and dose assignment of patient i, respectively, i = 1, . . . , N . In particular,
Yi = 1 (or 0) represents that patient i experiences (or does not experience) DLT within the
assessment window. Since patients enter clinical trials at random time, it is often the case that
when the (N + 1)-th patient is eligible for enrollment, some previously enrolled patients are still
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being followed without definitive DLT outcomes, thus their DLT outcomes Yi’s are unknown. Let
Bi be the indicator for an unknown DLT outcome, where Bi = 1 (or 0) denotes that the DLT
outcome of patient i is unknown (or observed). We write nd =
∑N
i=1 1(Yi = 1, Zi = d,Bi = 0) and
md =
∑N
i=1 1(Yi = 0, Zi = d,Bi = 0) the numbers of patients with observed DLTs and non-DLTs,
respectively. In addition, we use rd =
∑N
i=1 1(Zi = d,Bi = 1) to denote the number of patients
with pending outcomes and write Id = {i : Zi = d,Bi = 1} the index set of these patients. Lastly,
we denote Sd =
∑N
i=1 1(Yi = 1, Zi = d,Bi = 1) the number of DLTs among the rd pending patients
that would have been seen had these patients finished their DLT assessment. Since these patients
are still being followed, {Yi : i ∈ Id} are not observed and are random variables, and so as Sd. We
have Sd ∈ {0, 1, . . . , rd}. The following figure summarizes the patient statistics at dose d.
Total (nd +md + rd)
rd pending
(rd − Sd) non-DLTs
Sd DLTs (random)
md non-DLTs
nd DLTs
If Sd is known, then the dose-finding decision is given by Ad = A(nd +Sd,md + rd−Sd), where
A is the decision function of mTPI-2 (Section 2). However, since Sd is not observed and random,
the decision Ad becomes a random variable too. Suppose through statistical inference one could
calculate the posterior probability Pr(Sd = s | data), then we define
Pr(Ad = a | data) =
∑
s:A(nd+s,md+rd−s)=a
Pr(Sd = s | data), (2)
which gives the PoD for each decision a ∈ {−1, 0, 1} based on mTPI-2. Details about the prob-
ability model and statistical inference are described in the next section. If d is the lowest dose,
de-escalation is not possible. Similarly, if d is the highest dose, escalation is not possible. To
ensure that the PoD is well defined, in Supplementary Section S1 we show that Pr(Ad = a | data)
sums up to 1 over the space of a. If there is no pending patient at the current dose (rd = 0), we
have Sd ≡ 0, and Ad ≡ A(nd,md), i.e., the mTPI-2 decision.
Next, define `(Ad = a,A
true
d = b) the loss of making dose decision a if b is the true dose decision
that should have been made. We consider the 0-1 loss,
`(a, b) =
1, if a 6= b;0, if a = b, for a, b ∈ {−1, 0, 1}. (3)
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Let A∗d = min{arg maxa Pr(Ad = a | data)} denote the most conservative decision within the set
of decisions that have the highest PoD. In other words, if arg maxa Pr(Ad = a | data) returns a
single decision among {−1, 0, 1}, then A∗d equals that decision. Otherwise, if multiple decisions
tie for the highest PoD, we choose the more conservative one using the “min” function. It is easy
to see that the dose decision A∗d minimizes the posterior expected loss under the loss function (3)
thus is the optimal decision to make, i.e., Bayes’ rule.
Denote by γd,a = Pr(Ad = a | data) for a ∈ {−1, 0, 1}. To ensure the safety of the design, we
introduce two essential suspension rules.
If A∗d = 1, i.e. escalation: We suspend the trial if (i) γd,1 < piE for some threshold piE ∈
[0.33, 1] or (ii) md = 0. Condition (i) reflects that escalation is not allowed if the
confidence of escalation is less than piE. A larger piE represents more conservative dose
escalations. Condition (ii) means escalation is not allowed until at least one patient at
the current dose has finished the DLT assessment and does not experience DLT, similar
to the rule in Normolle and Lawrence (2006).
If A∗d = 0, i.e. stay: We suspend the trial if γd,−1 > piD for some threshold piD ∈ [0, 0.5]. This
means stay is not allowed if there is a relatively high chance of de-escalation. A smaller
piD represents more conservative stays.
If none of the suspension rule is triggered, the optimal decision A∗d is made. In real applications,
the values piE and piD should be chosen according to the desired extent of safety. To ensure safety,
we recommend choosing piE ≥ 0.8 and setting piD ≤ 0.25. For example, in the simulation studies
(Section 6), we use piE = 1 and piD = 0.15, which eliminate the chance of risky escalations. We
will discuss more about the important role of piE and piD in Section 6. The dose assignment rules
of PoD-TPI is summarized in Algorithm 1.
For practical concerns, similar to existing designs (for example, Ji et al., 2010 and Yuan et al.,
2018), we include the following two safety rules in PoD-TPI throughout the trial.
Safety rule 1 (early termination): At any moment in the trial, if n1 + m1 ≥ 3 and Pr(p1 >
pT | n1,m1) > 0.95, terminate the trial due to excessive toxicity;
Safety rule 2 (dose exclusion): At any moment in the trial, if nd + md ≥ 3 and Pr(pd > pT |
nd,md) > 0.95, suspend dose d and higher doses from the trial.
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Algorithm 1 Dose assignment rule of PoD-TPI. Current dose level is d.
1: if rd = 0 then
2: Assign the patient to dose d+A(nd,md)
3: else if rd > 0 then
4: Calculate γd,a = Pr(Ad = a | data) and A∗d = min{arg maxa Pr(Ad = a | data)}
5: if A∗d = 1 then
6: if γd,1 < piE or md = 0 then
7: Suspend accrual
8: else
9: Assign the patient to (d+ 1)
10: end if
11: else if A∗d = 0 then
12: if γd,−1 > piD then
13: Suspend accrual
14: else
15: Assign the patient to d
16: end if
17: else if A∗d = −1 then
18: Assign the patient to (d− 1)
19: end if
20: end if
In other words, if a sufficient number (≥ 3) of patients has been treated at dose d with observed
outcomes, and these outcomes suggest d is deemed higher than the MTD, then this dose and higher
doses are excluded from the trial. The posterior probability Pr(pd > pT | nd,md) is calculated
using the observed data at dose d with a prior distribution pd ∼ Beta(1, 1). It is possible that a
dose d and higher doses are excluded when some outcomes at d are pending. In this case, we allow
these doses to be re-included if the pending outcomes are observed later and the safety rule is no
longer violated. If safety rule 1 is triggered while some outcomes at the lowest dose are pending,
we suspend the trial. The trial is resumed if the pending outcomes are observed later and the
safety rule is no longer violated, and the trial is permanently terminated otherwise.
9
The trial is completed if the number of enrolled patients reaches the pre-specified maximum
allowable sample size N∗ or safety rule 1 is triggered. The last step is to recommend an MTD
based on the DLT outcomes. If the trial is terminated due to safety rule 1, no MTD is selected.
Otherwise, after DLT assessment for all patients is finished, we use the same procedure as in Ji
et al. (2007) to report an MTD. See Supplementary Section S2 for details.
4 Probability Model
4.1 Likelihood Construction
We construct the likelihood function for the observed data, with which we make inference about
the distribution of the time to DLT and calculate the posterior distribution of Sd and Ad (Equation
2).
We first introduce some additional notation. Let τ denote the length of the DLT assessment
window. In oncology, τ is usually 21 or 28 days, corresponding to a cycle of treatment. Denote
by Ti the time to DLT for patient i, i = 1, . . . , N ; recall that we assume N patients have been
treated. By definition, Yi = 1(Ti ≤ τ), because Yi represents whether patient i experiences DLT
within the assessment window. Conditional on the dose assignments (Zi’s), the Ti’s are assumed
to be independent and identically distributed with probability density function fT |Z and survival
function ST |Z .
Next, the following notations are defined with respect to the time when the (N + 1)-th patient
is available for enrollment. To simplify notation, we do not explicitly write out the dependency on
time. Let Ui = min{τ, eN+1− ei} denote the potential censoring time for patient i, where ei is the
enrollment time for patient i, and (eN+1 − ei) is the time between the enrollment time of patient
i and the time when the new patient (N + 1) becomes available. Let Vi = min{Ti, Ui} denote the
follow-up time, and let δi = 1(Ti ≤ Ui) indicate whether the DLT is observed (δi = 1) or censored
(δi = 0). We note that the case {δi = 1} corresponds to {Yi = 1, Bi = 0}, and {δi = 0} includes
{Yi = 0, Bi = 0} and {Bi = 1}.
Based on survival modeling (see, e.g., Klein and Moeschberger, 2006), patients with observed
DLTs (δi = 1) contribute fT |Z to the likelihood, and patients with censored observations (δi = 0)
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contribute ST |Z to the likelihood. Therefore, the likelihood function is
L =
N∏
i=1
[
fT |Z(vi | zi)1(δi=1)ST |Z(vi | zi)1(δi=0)
]
. (4)
We define a model for fT |Z(vi | zi) next.
4.2 Sampling Model for Time to Toxicity
We assume a parametric distribution for Ti as follows. First, as in the mTPI-2 design, we assume
Pr(Ti ≤ τ | Zi = d, pd) = Pr(Yi = 1 | Zi = d, pd) = pd. (5)
That is, with probability pd, the DLT for a patient treated by dose d occurs within (0, τ ].
Conditional on [Ti ≤ τ ] (i.e., [Yi = 1]), we assume a piecewise uniform distribution for [Ti | Yi =
1, Zi = d] on the interval (0, τ ]. That is, we partition (0, τ ] into K sub-intervals {(hk−1, hk], k =
1, . . . , K}, where 0 = h0 < h1 < · · · < hK = τ . For simplicity, we consider K = 3 sub-intervals
with equal length, hk = kτ/K for k = 0, 1, 2, 3. The k-th sub-interval is assigned a weight wk,
and
∑K
k=1wk = 1. Conditional on [Yi = 1, Zi = d], Ti falls into (hk−1, hk] with probability wk and
follows a uniform distribution within this interval. The conditional probability density function
of [Ti | Yi = 1, Zi = d] is thus
fT |Y,Z(t | Yi = 1, Zi = d,w) = wk · 1
hk − hk−1 , for hk−1 < t ≤ hk. (6)
Implicitly in (6), Ti and Zi are conditionally independent given [Ti ≤ τ ], meaning the conditional
distribution of the time to DLT is the same across doses. In other words, the parameter w is shared
across doses. As toxicity data are typically sparse in phase I trials, the conditional independence
assumption allows borrow of information across doses and helps the estimation of w.
Next, according to the law of total probability,
fT |Z(t | Zi = d, pd,w)
=
∑
y∈{0,1}
fT |Y,Z(t | Yi = y, Zi = d,w) Pr(Yi = y | Zi = d, pd)
= pd · wk · 1
hk − hk−1 , for hk−1 < t ≤ hk.
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Here, fT |Y,Z(t | Yi = 0, Zi = d,w) = 0 for t ≤ τ , since {Yi = 0} indicates {Ti > τ}. The survival
function of Ti is
ST |Z(t | Zi = d, pd,w) = 1−
∫ t
0
fT |Z(v | Zi = d, pd,w) dv
= 1− pd
K∑
k=1
wkβ(t, k), for t ≤ τ,
where
β(t, k) =

1, if v > hk;
t−hk−1
hk−hk−1 , if v ∈ (hk−1, hk], k = 1, . . . , K;
0, otherwise.
Finally, writing out the parametric forms of fT |Z and ST |Z in Equation (4), we obtain the
likelihood of p and w,
L , L(p,w | data) ∝
K∏
k=1
wn·kk
D∏
d=1
{
pndd (1− pd)md
∏
i∈Id
[
1− pd
K∑
k=1
wkβ(vi, k)
]}
. (7)
Here, n·k =
∑
i:yi=1
1(hk−1 < vi ≤ hk) is the number of patients (across all doses) who have
experienced DLT in the time interval (hk−1, hk]. The pending patients’ follow-up times are included
in the likelihood (7) via β(vi, k). If the DLT outcomes are fully observed, i.e., Id = ∅, the likelihood
of pd reduces to the Bernoulli likelihood (1).
4.3 Prior and Posterior
We complete the probability model with prior models for the parameters p = (p1, . . . , pD) and
w = (w1, . . . , wK). We assume
pd ∼ Beta(θd1, θd2), and w ∼ Dir(η1, . . . , ηK). (8)
Here, θd1 and θd2 can be chosen based on prior guess of the DLT probability of each dose, and
(η1, . . . , ηK) can be chosen based on prior knowledge of the time to DLT falling into each sub-
interval. If such information is not available, we recommend simply setting θd1 = θd2 = 1 and
η1 = · · · = ηK = 1.
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Posterior of Ad. With the likelihood (7) and the prior model (8), we can conduct posterior
inference on p and w. Specifically,
pi(p,w | data) ∝
D∏
d=1
pi0(pd)× pi0(w)× L(p,w | data),
where pi0(pd) and pi0(w) are the prior models as in (8). Markov chain Monte Carlo simulation is
used to draw samples from the posterior distribution pi(p,w | data).
Based on the sampling models (5) and (6), we can calculate the probability that a patient
experiences DLT within the assessment window given the patient has been followed for vi (< τ)
without DLT, i.e., the conditional probability of {Yi = 1} for i ∈ Id. Recall that Id contains the
indices of the pending patients. For a patient i ∈ Id, we have
qi(vi, d, pd,w) , Pr(Yi = 1 | Ti > vi, Zi = d, pd,w)
=
Pr(Ti > vi | Yi = 1, Zi = d,w) Pr(Yi = 1 | Zi = d, pd)∑1
y=0 Pr(Ti > vi | Yi = y, Zi = d,w) Pr(Yi = y | Zi = d, pd)
=
[
1−∑Kk=1wkβ(vi, k)] pd[
1−∑Kk=1wkβ(vi, k)] pd + (1− pd) , (vi < τ).
Recall that Sd is the number of patients that will experience DLTs among the pending patients
at dose d. Therefore, mathematically Sd =
∑
i∈Id Yi. By definition, given the observed data
(including the pending patients’ follow-up times), [Sd | pd,w, data] follows a Poisson binomial
distribution,
Sd | pd,w, data ∼ Poisson-binomial(qi, i ∈ Id).
Here, the Poisson binomial distribution is the distribution of the sum of independent Bernoulli
random variables that not necessarily have the same success probabilities. See, for example, Chen
and Liu (1997) for an introduction. Furthermore, we have
Pr(Sd = s | data) =
∫
w
∫
pd
Pr(Sd = s | pd,w, data)pi(pd,w | data)dpd dw.
This integral can be approximated using posterior samples of pd and w. Finally, we can calculate
Pr(Ad = a | data) according to Equation (2).
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5 Hypothetical Trial Examples
We illustrate the PoD-TPI design through two hypothetical trials in Figure 1. Suppose the
target DLT probability is pT = 0.3, and the DLT assessment window is τ = 28 days. We use
1 = 2 = 0.05 as the bounds of the equivalence interval. In addition, we set the thresholds piE = 1
and piD = 0.15 for trial suspension, and let θd1 = θd2 = 1 and η1 = · · · = ηK = 1. In the first
trial, by the time the new patient 7 arrives on day 63, 6 patients have been treated at dose d,
among whom patients 1, 2, 3 and 4 have observed outcomes with two DLTs and two non-DLTs
(nd = 2 and md = 2). The times to DLTs for patients 3 and 4 are t3 = 9 days and t4 = 26 days,
respectively. Patients 5 and 6 are still pending (rd = 2) with follow-up times v5 = 15 days and
v6 = 8 days. Assume d is neither the lowest dose nor the highest dose, thus both de-escalation
and escalation are possible. Via the probability model introduced in Sections 3 and 4, using the
observed DLT data on patients 1–4 and time-to-event data on patients 5 and 6, PoD-TPI estimates
Pr(Sd = 2 | data) = 0.12, Pr(Sd = 1 | data) = 0.46 and Pr(Sd = 0 | data) = 0.42 and calculates
the PoDs Pr(Ad = a | data), as seen in Figure 1. De-escalation (Ad = −1) has the highest PoD,
and PoD-TPI recommends de-escalating the dose for patient 7 although two patients are still
pending. In this way, PoD-TPI saves time and avoids trial suspension compared to mTPI-2. In
the second trial, the only difference is that patient 4 does not have a DLT (nd = 1 and md = 3).
In this case, Pr(Sd = 2 | data) = 0.03, Pr(Sd = 1 | data) = 0.30 and Pr(Sd = 0 | data) = 0.67.
Escalation has the highest PoD, which is 0.67. However, the PoD of escalation does not reach the
safety threshold piE, meaning there is a chance (0.33) that escalation is not preferred. In practice,
overly aggressive escalations can cause tremendous risk to patients, thus we use a conservative
threshold piE = 1 to prevent risky escalations even though the PoD for escalation is 0.67, the
largest. Enrollment is suspended, and patient 7 is turned away. Later, a new patient (still labeled
as the 7th patient in the trial) arrives on day 77, and by this time it turns out that patients 5 and
6 had DLTs. Therefore, the dose is de-escalated for patient 7. In this way, PoD-TPI avoids the
risky escalation and maintains the safety of the trial.
Differences with other TITE designs. The two trial examples highlight the key feature
of PoD-TPI: the use of posterior distribution of decisions. In the other TITE designs, such as
TITE-CRM, TITE-BOIN and TITE-keyboard, the pending outcomes and the follow-up times are
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Figure 1: Two hypothetical dose-finding trials using the PoD-TPI design. In both trials, by the
time patient 7 arrives, patients 1, 2, 3 and 4 have observed outcomes, and patients 5 and 6 are
still being followed without definitive outcomes. In trial 1, based on the posterior probabilities of
decisions, patient 7 is assigned to the next lower dose. In trial 2, due to safety concerns, the trial
is suspended, and patient 7 is turned away. After the pending outcomes are observed, the next
patient is assigned to the next lower dose.
incorporated into the survival likelihood (7) to help estimate pd. Dose decision is then based on
inference about pd, instead of the PoDs of the decisions. For example, TITE-CRM is an extension
of the CRM (O’Quigley et al., 1990) and models pd using a parametric curve, pd = φ(d, α). Here α
is the parameter that defines the dose-toxicity curve, e.g., a regression parameter in a power curve
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as pd = p
exp(α)
0d , where p0d’s are pre-specified. Then, a weighted likelihood for α is constructed
through survival modeling,
L(α | data) =
N∏
i=1
[ρiφ(zi, α)]
1(δi=1) [1− ρiφ(zi, α)]1(δi=0) .
The value ρi is the weight of patient i, ρi = 1 if the patient has observed outcome, and ρi =
ρ(vi) ∈ [0, 1] otherwise. By default, ρ(vi) = vi/τ . TITE-BOIN is an extension of the BOIN design
(Liu and Yuan, 2015), which estimates pd by
pˆd ∝
nd +
nd+0.5pT
md+1−0.5pT
[
rd −
∑
i∈Id(vi/τ)
]
nd +md + rd
.
TITE-keyboard is an extension of the keyboard design (Yan et al., 2017), which estimates pd
through the likelihood,
L(pd | data) = pndd (1− pd)md
∏
i∈Id
(1− ρipd).
Again, ρi is the weight of patient i. In either cases, one can conduct inference on pd and make
a dose decision based on the same rules in CRM, BOIN or keyboard. In contrast, PoD-TPI
takes a different approach by making inference on decisions. The advantage of PoD-TPI over
existing TITE designs is that PoD-TPI formally takes into account the variability of the pending
outcomes and uses probability cutoffs to control the chance of risky decisions. Consider the
second trial example in Figure 1. When patient 7 arrives on day 63, using the TITE-CRM, TITE-
BOIN or TITE-keyboard designs, based on the estimate of pd, patient 7 will be treated by the
next higher dose (d + 1). However, as the outcomes of patients 5 and 6 turn out to be DLTs
later, the escalation decision puts patient 7 in an overly toxic dose. Such decisions are of major
concern to safety committees as they tend to expose patients to unnecessary risks. Some designs
take additional steps to suspend enrollment to enhance safety. For example, TITE-BOIN has a
suspension rule when more than 50% of the outcomes at the current dose are pending, and TITE-
keyboard has a suspension rule when fewer than two patients at the current dose level have been
completely followed. Nevertheless, as in this example, such suspension rules cannot fully account
for the variability of the pending outcomes and the risks of different decisions and would still allow
the risky escalation.
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6 Numerical Studies
We conduct extensive computer simulations to assess the operating characteristics of the proposed
PoD-TPI design. The implementation of PoD-TPI requires the specification of a few parameters,
piE, piD, (θd1, θd2) and (η1, . . . , ηK), in the suspension rule and prior model. We use piE = 1,
piD = 0.15, θd1 = θd2 = 1 and η1 = · · · = ηK = 1. Note that piE = 1 means that escalation must
have PoD equal to 1 to be selected as the dose decision when there are pending patients.
We consider the 60 dose-toxicity scenarios reported in Guo et al. (2019), which cover different
target DLT probabilities pT ∈ {0.10, 0.17, 0.30}, numbers of doses D ∈ {3, 4, 5, 6} and dose-toxicity
curves. See Supplementary Table S1. To obtain the mTPI-2 decision rule A, it is necessary to
define the equivalence interval. We use 1 = 2 = 0.03 when pT = 0.10, and 1 = 2 = 0.05 when
pT = 0.17 or 0.30. As in typical phase I oncology trials, we set the length of the DLT assessment
period at τ = 28 days. For a scenario with a total of D doses, we use a maximum sample size of
6D patients. We generate the arrival time between two consecutive patients from an exponential
distribution with rate δ per day, meaning the average inter-arrival time is 1/δ days. The time to
DLT for a patient treated by dose d is generated from a Weibull distribution with shape ζd and
scale λd,
(Ti | Zi = d) ∼Weibull(ζd, λd),
such that Pr(Ti ≤ τ | Zi = d) = pd. To uniquely identify ζd and λd, we impose another constraint,
Pr(Ti ≤ (1− γ)τ | Zi = d) = (1− α)pd for some 0 < γ < 1 and 0 < α < 1, which means if a DLT
occurs within the assessment window, with probability α it occurs within the last fraction of γ.
This leads to
ζd = log
[
log(1− pd)
log(1− pd + αpd)
]/
log
(
1
1− γ
)
, λd =
τ
[− log(1− pd)]1/ζd
.
For each dose-toxicity scenario, we consider the following four settings that cover different accrual
rates and DLT time profiles.
Setting 1: inter-arrival time is 10 days, and 50% of DLTs occur in the second half of the assess-
ment window, meaning δ = 0.1, α = 0.5 and γ = 0.5;
Setting 2: inter-arrival time is 5 days, and 50% of DLTs occur in the second half of the assessment
window, meaning δ = 0.2, α = 0.5 and γ = 0.5;
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Setting 3: inter-arrival time is 10 days, and 80% of DLTs occur in the last quarter of the assess-
ment window, meaning δ = 0.1, α = 0.8 and γ = 0.25.
Setting 4: inter-arrival time is 5 days, and 80% of DLTs occur in the last quarter of the assessment
window, meaning δ = 0.1, α = 0.8 and γ = 0.25.
We do not directly consider a setting with a different length of assessment window, as it is equiv-
alent to varying the accrual rate after rescaling the time. Finally, for each scenario and accrual
rate and DLT time setting, we simulate 1,000 trials using PoD-TPI as the design.
The performance of the PoD-TPI design is first evaluated based on its reliability and safety.
Specifically, the reliability can be measured by the percentage of trials that the MTD is correctly
selected (PCS), and the safety can be measured by the average percentages of patients that are
correctly allocated to the MTD (percentage of correct allocation, PCA) and are allocated to doses
higher than the MTD (percentage of overdosing allocation, POA). Furthermore, we calculate the
percentage of trials concluding a dose above the true MTD (percentage of overdosing selection,
POS) and the average percentage of toxicity outcomes (POT). The average trial duration is also
reported.
In addition to the metrics mentioned above, as noted in Section 5, a major concern for designs
allowing patient enrollment with pending DLT information is the possibility of making an incon-
sistent decision, which is another important aspect of reliability and safety. Here, an inconsistent
decision refers to a decision that is different from what would be made if complete outcomes were
observed. There are six types of inconsistent decisions: (1) should de-escalate but stayed (DS),
(2) should de-escalate but escalated (DE), (3) should stay but escalated (SE), (4) should stay but
de-escalated (SD), (5) should escalate but de-escalated (ED), and (6) should escalate but stayed
(ES). DE and SE are the most risky decisions, as they can expose patients to overly toxic doses.
DS is also risky for the same reason. SD, ED and ES are conservative decisions, which can allocate
too many patients to sub-therapeutic doses but are less severe than the overly aggressive decisions.
The performance of PoD-TPI is benchmarked against mTPI-2, which can be seen as a per-
formance upper bound. In addition, we implement R-TPI, TITE-CRM and TITE-BOIN for
comparison. Specifically, for TITE-CRM, we use the empiric model, pd = φ(d, α) = p
exp(α)
0d . The
skeleton p0d’s are chosen based on Lee and Cheung (2009) using an initial MTD guess of dD/2e;
the prior for α is N(0, 1.342). The mTPI-2 can only make dose assignments with complete DLT
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outcomes, thus we suspend accrual after treating each cohort of patients until all DLT outcomes
are fully observed. By default, for R-TPI, the trial is suspended if more than 3 patients at the
current dose are still being followed without outcomes. For TITE-CRM, available patients are
always enrolled without suspension. For TITE-BOIN, the trial is suspended if more than half of
the outcomes at the current dose are pending. The same safety rules (Section 3) are applied to
all designs. Also, dose escalation is prohibited until at least one patient at the current dose has
finished DLT assessment without experiencing toxicity (Normolle and Lawrence, 2006).
The simulation results are summarized in Tables 1 and 2, which show averages over the 60 dose-
toxicity scenarios. The scenario-specific operating characteristics are reported in Supplementary
Figures S1 and S2. The PCS, PCA, POA, POS and POT of PoD-TPI, reported in Table 1, are
comparable to those of mTPI-2. On average, the trial duration is shortened by 70 days using
PoD-TPI compared to mTPI-2. On the other hand, R-TPI, TITE-CRM and TITE-BOIN also
yield performances generally comparable to those of mTPI-2. We note that the duration of the
trial solely depends on the suspension rules, i.e. how many times an available patient is turned
away. As a result, TITE-CRM achieves the optimal trial speed as it does not have a suspension
rule. However, the reliability of TITE-CRM is decreased when accrual is fast (Settings 2 and 4).
The frequencies of inconsistent decisions are reported in Table 2, where the dose assignment
decisions of the TITE designs are compared with the decisions that would be made by mTPI-2
if complete outcomes were observed. An alternative way of defining inconsistent decisions is to
compare each TITE decision with its complete data counterpart, e.g., comparing TITE-CRM with
CRM and comparing TITE-BOIN with BOIN. The frequencies of inconsistent decisions defined
in this way is reported in Supplementary Table S2, which is similar to those reported in Table
2. As discussed in Section 5, the chance of making inconsistent decisions is a major concern for
drug companies and regulatory agencies. It is impossible to eliminate inconsistent decisions in
the presence of pending outcomes, but the chance of making such decisions can be controlled by
suspension rules. We report a few summaries of Table 2.
1. By applying confidence thresholds to decisions, PoD-TPI has the smallest frequencies of risky
inconsistent decisions (DS, DE and SE) among all designs.
2. In particular, PoD-TPI never makes risky escalations (DE and SE).
3. Notably, on average, the frequency of overly conservative inconsistent decisions made by PoD-
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Table 1: Performance of PoD-TPI compared with mTPI-2, R-TPI, TITE-CRM and TITE-BOIN.
Values shown are averages over simulated trials and the 60 dose-toxicity scenarios. The unit of
PCS, PCA, POA, POS and POT is %, and the unit of duration (Dur) is day.
Method PCS PCA POA POS POT Dur
Setting 1
mTPI-2 52.3 38.2 24.9 17.5 16.3 458
R-TPI 51.0 38.9 22.8 15.6 15.7 400
TITE-CRM 51.2 38.4 24.3 28.1 16.3 280
TITE-BOIN 51.7 37.3 25.2 24.8 16.3 336
PoD-TPI 52.2 38.2 24.0 17.4 16.1 389
Setting 2
mTPI-2 52.5 38.0 25.8 17.9 16.4 339
R-TPI 51.4 38.4 22.9 15.8 15.8 300
TITE-CRM 48.6 34.9 18.2 29.7 14.4 155
TITE-BOIN 51.4 37.1 24.6 23.8 16.1 227
PoD-TPI 51.5 37.6 23.2 17.2 15.8 265
Setting 3
mTPI-2 53.1 38.3 25.3 17.5 16.3 469
R-TPI 52.0 38.8 24.6 16.6 16.3 413
TITE-CRM 52.4 37.6 27.0 27.3 17.0 282
TITE-BOIN 52.0 37.0 27.4 26.2 17.0 343
PoD-TPI 52.3 37.9 24.4 17.8 16.2 402
Setting 4
mTPI-2 52.7 38.1 25.9 17.5 16.5 351
R-TPI 51.8 38.1 24.5 17.2 16.2 315
TITE-CRM 49.6 34.0 22.7 29.6 15.5 156
TITE-BOIN 52.1 36.7 27.5 26.1 16.9 234
POD-TPI 51.5 37.6 24.0 17.5 16.1 279
TPI is also the smallest among all designs.
We note that the inconsistent decisions do not necessarily affect the metrics like PCS, PCA,
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POA, POS and POT, since the selection of MTD is always based on complete data. Also, the
inconsistent decisions can be either too aggressive or too conservative thus cancel out in the
calculation of PCA and POA. Instead, the inconsistent decisions are more about patients and
their risks of being exposed to toxic doses. If a dose escalation decision has large uncertainty, it is
unethical to expose future patients to higher doses, and the safety review boards should express
concerns regarding such decision. From this point of view, PoD-TPI is more favorable compared
to the other TITE designs.
Sensitivity analysis. An attractive feature of PoD-TPI is the flexibility in calibrating the values
of piE and piD to achieve the desired trade-off between speed and safety. The threshold piE controls
the rates of DE and SE decisions, and piD controls the rate of SD decisions. They both affect the
speed of the trial through suspension rules.
We conduct additional simulations to demonstrate the performance of PoD-TPI with five
combinations of piE and piD. The results are summarized in Table 3. By setting piE = 1 and
piD = 0, we achieve the safest version of PoD-TPI, which never makes any inconsistent and risky
decision (DS, DE and SE) and has the highest PCA and the lowest POA. As a trade-off, the trial
duration of the safest version is longer than that of the default version by 20 days. On the other
hand, by setting piE = 0.8 and piD = 0.25, we obtain the fastest version of PoD-TPI, the speed of
which is comparable to TITE-BOIN. The trial duration of the fastest version is shorter than that
of the default version by 50 days. As a trade-off, the safety profile of the fastest version is worse
than the other versions.
Benchmark against rolling six. The rolling six (R6) design (Skolnik et al., 2008) is a widely
used phase I design that allows for continual accrual of up to six patients onto a dose level. So far,
it has 139 citations (according to Google Scholar) and was used in many real-world trials (e.g.,
Mosse´ et al., 2013 and von Stackelberg et al., 2016). R6 consists of a set of algorithmic decision
rules that determine the dose-finding decisions and MTD selection. The rules are transparent and
are interpretable to clinicians.
We conduct additional simulations to benchmark the performance of PoD-TPI against R6.
The aim is to show that PoD-TPI has a lower risk than R6, thereby further establish the potential
utility of the PoD-TPI design in practice. For a fair comparison, we consider the 20 dose-toxicity
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Table 2: Frequencies of inconsistent decisions compared to the decisions that would be made by
mTPI-2 if complete outcomes were observed. Values are shown in 1/103. The decisions in square
brackets are inconsistent and risky.
Method [DS] [DE] [SE] SD ED ES Sum
Setting 1
R-TPI 30.7 0.0 0.0 0.0 0.0 93.7 124.4
TITE-CRM 99.3 4.1 14.6 4.8 1.5 108.1 232.4
TITE-BOIN 10.9 5.8 30.4 46.6 0.2 20.4 114.3
PoD-TPI 6.1 0.0 0.0 25.0 1.0 7.9 40.0
Setting 2
R-TPI 40.3 0.0 0.0 0.0 0.0 84.3 124.6
TITE-CRM 66.2 3.8 14.7 2.7 1.0 69.8 158.2
TITE-BOIN 15.3 6.7 26.8 51.5 0.6 33.7 134.6
PoD-TPI 7.8 0.0 0.0 43.9 0.3 20.9 72.9
Setting 3
R-TPI 49.3 0.0 0.0 0.0 0.0 94.4 143.7
TITE-CRM 103.6 7.8 18.3 6.1 2.9 92.6 231.3
TITE-BOIN 22.9 11.3 40.0 39.8 0.1 17.5 131.6
PoD-TPI 11.7 0.0 0.0 23.1 1.1 9.8 45.7
Setting 4
R-TPI 57.5 0.0 0.0 0.0 0.0 89.9 147.4
TITE-CRM 53.3 7.2 19.8 3.1 1.7 50.9 136.0
TITE-BOIN 31.1 12.1 37.8 41.4 0.4 28.1 150.9
POD-TPI 16.7 0.0 0.0 35.9 0.4 23.6 76.6
scenarios with a target DLT probability of pT = 0.17 and calibrate the maximum sample size of
PoD-TPI to match the average sample size of R6. Specifically, for each scenario, we first simulate
1,000 trials using R6 as the design. Next, we calculate the average sample size for R6 across the
simulated trials. Finally, we round up the average sample size for R6 and use it as the maximum
sample size for PoD-TPI. The average sample size of R6 across the 20 scenarios is around 19
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Table 3: Performance of PoD-TPI with different choices of piE and piD. Values shown are averages
over simulated trials and the 60 dose-toxicity scenarios. The unit of PCS, PCA and POA is %,
the unit of inconsistent decisions (DS, DE, SE, SD, ED, ES) is 1/103, and the unit of duration
(Dur) is day. The decisions in square brackets are inconsistent and risky.
piE piD PCS PCA POA Dur [DS] [DE] [SE] SD ED ES
Setting 1
(mTPI-2) 52.3 38.2 24.9 458 0.0 0.0 0.0 0.0 0.0 0.0
1 0.15 52.2 38.2 24.0 389 6.1 0.0 0.0 25.0 1.0 7.9
1 0 51.8 38.2 23.8 410 0.0 0.0 0.0 24.9 1.1 7.3
0.9 0.25 51.9 38.0 24.5 352 11.5 1.5 5.0 25.5 1.2 11.5
0.9 0.15 52.0 37.9 24.5 359 6.1 1.5 5.1 25.5 1.0 7.9
0.8 0.25 52.2 37.9 25.2 336 11.8 4.0 11.2 25.7 1.2 11.1
Setting 2
(mTPI-2) 52.5 38.0 25.8 339 0.0 0.0 0.0 0.0 0.0 0.0
1 0.15 51.5 37.6 23.2 265 7.8 0.0 0.0 43.9 0.3 20.9
1 0 51.5 37.7 22.9 285 0.0 0.0 0.0 43.0 0.3 19.4
0.9 0.25 51.4 37.3 23.9 231 13.6 1.9 6.6 44.4 1.5 28.5
0.9 0.15 51.7 37.5 24.0 237 7.8 1.9 6.7 45.1 1.1 20.0
0.8 0.25 51.2 36.9 24.5 221 13.7 4.2 13.0 44.6 1.6 27.7
Setting 3
(mTPI-2) 53.1 38.3 25.3 469 0.0 0.0 0.0 0.0 0.0 0.0
1 0.15 52.3 37.9 24.4 402 11.7 0.0 0.0 23.1 1.1 9.8
1 0 52.2 38.1 24.0 422 0.0 0.0 0.0 22.8 1.1 8.9
0.9 0.25 52.5 37.5 26.0 367 21.8 4.4 10.7 23.3 1.3 14.3
0.9 0.15 52.4 37.7 25.8 374 12.6 4.5 10.9 23.9 1.1 9.2
0.8 0.25 52.3 37.4 27.5 350 22.6 9.8 21.3 24.2 1.2 13.1
Setting 4
(mTPI-2) 52.7 38.1 25.9 351 0.0 0.0 0.0 0.0 0.0 0.0
1 0.15 51.7 37.6 23.9 279 16.9 0.0 0.0 36.3 0.4 23.9
1 0 51.5 37.7 23.2 299 0.0 0.0 0.0 36.0 0.3 21.7
0.9 0.25 52.1 36.9 25.9 246 28.9 6.1 14.5 37.0 1.3 31.1
0.9 0.15 52.0 37.2 26.0 253 18.1 6.1 15.3 38.0 0.7 21.7
0.8 0.25 52.1 36.5 27.6 236 29.7 11.7 25.9 38.0 1.4 29.1
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patients.
The simulation results of R6 and PoD-TPI are summarized in Tables 4 and 5. The trial speed
of R6 is faster than that of PoD-TPI. However, the reliability and safety of PoD-TPI are uniformly
better than R6. In practice, usually safety is the most important criterion, thus PoD-TPI is more
favorable compared to R6.
Table 4: Performance of PoD-TPI compared with rolling six (R6). Values shown are averages over
simulated trials and the 60 dose-toxicity scenarios. The unit of PCS, PCA, POA, POS and POT
is %, and the unit of duration (Dur) is day.
Method PCS PCA POA POS POT Dur
Setting 1
R6 48.4 34.2 24.9 27.7 17.5 245
PoD-TPI 50.5 37.6 19.4 14.8 13.5 299
Setting 2
R6 48.7 34.0 25.4 27.6 17.3 175
PoD-TPI 49.0 36.9 19.6 15.7 13.4 217
Setting 3
R6 48.4 34.1 25.4 27.6 17.4 251
PoD-TPI 49.8 37.2 19.7 16.2 13.4 311
Setting 4
R6 48.3 33.7 25.7 27.5 17.3 177
POD-TPI 49.6 36.9 19.8 15.4 13.4 225
7 Discussion
We have proposed the PoD-TPI design to accelerate phase I trials. We have developed a statistical
methodology to calculate the posterior distribution of a dose assignment decision in the presence
of pending toxicity outcomes. The posterior distribution directly reflects the confidence of all
possible decisions, and the optimal decision is computed under a decision-theoretic framework.
Intuitive suspension rules are added based on the risk of the optimal decision, minimizing the
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Table 5: Frequencies of inconsistent decisions compared to the decisions that would be made by
mTPI-2 if complete outcomes were observed. Values are shown in 1/103. The decisions in square
brackets are inconsistent and risky.
Method [DS] [DE] [SE] SD ED ES Sum
Setting 1
R6 118.1 0.0 43.0 0.0 0.0 183.7 344.8
PoD-TPI 4.5 0.0 0.0 17.8 1.6 3.5 27.4
Setting 2
R6 77.9 0.0 43.7 0.0 0.0 51.1 172.7
PoD-TPI 6.7 0.0 0.0 37.9 0.5 10.7 55.8
Setting 3
R6 95.4 0.0 42.3 0.0 0.0 180.9 318.6
PoD-TPI 9.6 0.0 0.0 22.8 1.8 3.9 38.1
Setting 4
R6 32.5 0.0 43.0 0.0 0.0 50.4 125.9
POD-TPI 14.4 0.0 0.0 43.2 0.5 13.2 71.3
chance of making inconsistent decisions. Specifically, the probability threshold for suspension can
be flexibly adjusted to balance between speed and safety.
The PoD-TPI design is built upon the mTPI-2 design. Nevertheless, the proposed strategy
can be applied to other model-free or model-assisted designs such as 3+3 (Storer, 1989), BOIN
(Liu and Yuan, 2015), keyboard (Yan et al., 2017) or i3+3 (Liu et al., 2019). It suffices to change
the deterministic decision function A according to the specific design.
The PoD-TPI design has an early stopping rule when the lowest dose is too toxic. If desired,
another early stopping rule can be added when the MTD has been identified with high confidence.
For example, when Pr(pd ∈ IE | data) > 0.95 for some dose level d.
In PoD-TPI, the likelihood of the unknown parameters p and w is constructed based on survival
modeling (Equation 7), which implicitly assumes that all of the study subjects will eventually
experience the event of interest (DLT) if they are followed long enough. Such assumption may not
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be valid for immunotherapies, because they may not induce DLT events at all in some patients.
In such cases, we can use a cure rate model (Boag, 1949), assuming with non-zero probability that
patients may never experience DLT. Little would change in the overall setup; see Supplementary
Section S4 for a discussion.
Finally, in practice, it is desirable to tabulate the dose decision rules of the design before
the trial begins, so that the rules are transparent and can be examined by clinicians. We note
that this is generally not possible for model-based or model-assisted time-to-event designs without
some approximation (see, e.g., Yuan et al., 2018 and Lin and Yuan, 2018). A future direction is to
explore what approximation is needed for PoD-TPI so that its decision rules can be pre-tabulated.
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Supplementary Materials
S1 Probability of Decisions
We show that the PoD
Pr(Ad = a | data) =
∑
s:A(nd+s,md+rd−s)=a
Pr(Sd = s | data)
sums up to 1 over the space of a ∈ {−1, 0, 1}. Note that for any s ∈ {0, 1, . . . , rd}, A(nd + s,md +
rd − s) ∈ {−1, 0, 1}. On the other hand, the support of Sd is {0, 1, . . . , rd}. Therefore,
Pr (Ad ∈ {−1, 0, 1} | data) =
∑
s∈{0,1,...,rd}
Pr(Sd = s | data) = 1.
S2 Selection of the MTD
The trial is completed if the number of enrolled patients reaches the pre-specified maximum
allowable sample size N∗ or safety rule 1 is triggered. The last step is to recommend an MTD
based on the DLT outcomes. If the trial is terminated due to safety rule 1, no MTD is selected.
Otherwise, after DLT assessment for all patients is finished, we use the same procedure as in
Ji et al. (2007) to report an MTD. The isotonically transformed posterior means are used as
estimates of pd’s subject to the order constraint p1 ≤ · · · ≤ pD. In particular, we first calculate
posterior means and variances of the DLT probabilities, {p˜1, . . . , p˜D} and {ν1, . . . , νD}. Then,
we solve the optimization problem, minimizing
∑D
d=1(pˆd − p˜d)2/νd subject to pˆj ≥ pˆi for j > i.
Such optimization can be done using the pooled adjacent violators algorithm, and {pˆ1, . . . , pˆD}
are estimated DLT probabilities satisfying the order constraint. Let D = {d : pˆd ∈ IE} and
D− = {d : pˆd ∈ IU}. The procedure of selecting the MTD is summarized in Algorithm 2. We note
that the recommended dose for the last patient needs not be the selected MTD.
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Algorithm 2 MTD selection rule. Here |D| is the cardinality of set D.
1: if |D| = 0 then
2: if |D−| ≥ 1 then
3: Select the highest dose in D− as the MTD
4: else
5: No MTD is selected
6: end if
7: else if |D| = 1 then
8: Select the dose in D as the MTD
9: else if |D| > 1 then
10: Let D0 = arg mind∈D |pˆd − pT|
11: if |D0| = 1 then
12: Select the dose in D0 as the MTD
13: else if |D0| > 1 then
14: Let D0− = {d : pˆd ∈ D0, pˆd ∈ [pT − 1, pT]}
15: if |D0−| ≥ 1 then
16: Select the highest dose in D0− as the MTD
17: else
18: Select the lowest dose in D0 as the MTD
19: end if
20: end if
21: end if
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S3 Simulation Details
We provide supplementary tables and figures that are referenced in the manuscript. Table S1
summarizes the 60 dose-toxicity scenarios used in the simulation studies. Tables S2 and S3 report
the frequencies of inconsistent decisions by comparing the decisions made by R-TPI, TITE-CRM,
TITE-BOIN and PoD-TPI with their complete data counterparts. Figures S1 and S2 show the
scenario-specific operating characteristics.
Table S1: 60 dose-toxicity scenarios with different target DLT probabilities pT ∈ {0.10, 0.17, 0.30},
numbers of doses D ∈ {3, 4, 5, 6} and true DLT probabilities {p1, . . . , pD}.
Scn. pT D p1 p2 p3 p4 p5 p6
1 0.10 3 0.05 0.10 0.15
2 0.10 3 0.03 0.06 0.28
3 0.10 3 0.06 0.20 0.30
4 0.10 3 0.10 0.20 0.30
5 0.10 3 0.21 0.32 0.43
6 0.10 4 0.05 0.10 0.15 0.20
7 0.10 4 0.03 0.06 0.10 0.15
8 0.10 4 0.02 0.04 0.06 0.28
9 0.10 4 0.05 0.10 0.20 0.30
10 0.10 4 0.05 0.20 0.35 0.50
11 0.10 5 0.05 0.10 0.15 0.20 0.25
12 0.10 5 0.02 0.04 0.08 0.10 0.16
13 0.10 5 0.02 0.04 0.06 0.08 0.28
14 0.10 5 0.03 0.07 0.12 0.15 0.25
15 0.10 5 0.06 0.19 0.32 0.45 0.58
16 0.10 6 0.05 0.10 0.15 0.20 0.25 0.30
17 0.10 6 0.02 0.05 0.08 0.12 0.16 0.20
18 0.10 6 0.02 0.04 0.06 0.08 0.10 0.28
19 0.10 6 0.11 0.15 0.21 0.25 0.30 0.35
20 0.10 6 0.06 0.17 0.28 0.39 0.50 0.61
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Table S1: (continued)
Scn. pT D p1 p2 p3 p4 p5 p6
21 0.17 3 0.08 0.17 0.25
22 0.17 3 0.06 0.12 0.34
23 0.17 3 0.10 0.26 0.35
24 0.17 3 0.04 0.08 0.12
25 0.17 3 0.27 0.37 0.47
26 0.17 4 0.08 0.17 0.25 0.33
27 0.17 4 0.06 0.12 0.17 0.23
28 0.17 4 0.04 0.08 0.12 0.34
29 0.17 4 0.03 0.06 0.09 0.12
30 0.17 4 0.12 0.26 0.40 0.54
31 0.17 5 0.08 0.17 0.25 0.33 0.41
32 0.17 5 0.04 0.08 0.12 0.17 0.25
33 0.17 5 0.03 0.06 0.09 0.12 0.34
34 0.17 5 0.03 0.06 0.09 0.12 0.15
35 0.17 5 0.13 0.25 0.37 0.49 0.61
36 0.17 6 0.08 0.17 0.25 0.33 0.41 0.49
37 0.17 6 0.03 0.10 0.15 0.20 0.25 0.30
38 0.17 6 0.03 0.06 0.09 0.12 0.15 0.34
39 0.17 6 0.04 0.08 0.10 0.12 0.14 0.16
40 0.17 6 0.14 0.24 0.34 0.44 0.54 0.64
41 0.30 3 0.15 0.30 0.45
42 0.30 3 0.10 0.20 0.44
43 0.30 3 0.18 0.38 0.46
44 0.30 3 0.08 0.16 0.24
45 0.30 3 0.39 0.48 0.57
46 0.30 4 0.15 0.30 0.45 0.60
47 0.30 4 0.10 0.20 0.30 0.40
48 0.30 4 0.08 0.16 0.24 0.44
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Table S1: (continued)
Scn. pT D p1 p2 p3 p4 p5 p6
49 0.30 4 0.06 0.12 0.18 0.24
50 0.30 4 0.26 0.38 0.50 0.62
51 0.30 5 0.15 0.30 0.45 0.60 0.75
52 0.30 5 0.08 0.16 0.24 0.30 0.38
53 0.30 5 0.06 0.12 0.18 0.24 0.44
54 0.30 5 0.05 0.10 0.15 0.20 0.25
55 0.30 5 0.27 0.37 0.47 0.57 0.67
56 0.30 6 0.14 0.30 0.44 0.58 0.72 0.86
57 0.30 6 0.06 0.12 0.18 0.24 0.30 0.36
58 0.30 6 0.05 0.10 0.15 0.20 0.25 0.44
59 0.30 6 0.04 0.08 0.12 0.16 0.20 0.24
60 0.30 6 0.27 0.36 0.45 0.54 0.63 0.72
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Table S2: Frequencies of inconsistent decisions compared to the decisions that would be made by
the corresponding complete data design. R-TPI is compared to mTPI-2, TITE-CRM is compared
to CRM, TITE-BOIN is compared to BOIN, and PoD-TPI is compared to mTPI-2. Values are
shown in 1/103.
Method DS DE SE SD ED ES Sum
Setting 1
R-TPI 30.7 0.0 0.0 0.0 0.0 93.7 124.4
TITE-CRM 29.9 1.1 8.5 5.5 0.0 53.6 98.6
TITE-BOIN 11.0 5.8 15.2 46.6 0.2 31.8 110.6
PoD-TPI 6.1 0.0 0.0 25.0 1.0 7.9 40.0
Setting 2
R-TPI 40.3 0.0 0.0 0.0 0.0 84.3 124.6
TITE-CRM 20.8 0.5 10.4 4.7 0.0 70.3 106.7
TITE-BOIN 15.3 6.7 17.9 51.4 0.7 50.4 142.4
PoD-TPI 7.8 0.0 0.0 43.9 0.3 20.9 72.9
Setting 3
R-TPI 49.3 0.0 0.0 0.0 0.0 94.4 143.7
TITE-CRM 49.2 2.8 15.5 4.1 0.0 39.4 111.0
TITE-BOIN 22.9 11.3 25.9 39.8 0.1 27.7 127.7
PoD-TPI 11.7 0.0 0.0 23.1 1.1 9.8 45.7
Setting 4
R-TPI 57.5 0.0 0.0 0.0 0.0 89.9 147.4
TITE-CRM 30.6 1.9 18.2 2.7 0.0 37.2 90.6
TITE-BOIN 31.2 12.1 28.9 41.4 0.4 43.0 157.0
POD-TPI 16.7 0.0 0.0 35.9 0.4 23.6 76.6
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Table S3: Frequencies of inconsistent decisions compared to the decisions that would be made by
the corresponding complete data design. R6 is compared to complete-data R6, and PoD-TPI is
compared to mTPI-2. Values are shown in 1/103.
Method DS DE SE SD ED ES Sum
Setting 1
R6 41.8 0.0 0.0 0.0 0.0 146.1 187.9
PoD-TPI 4.5 0.0 0.0 17.8 1.6 3.5 27.4
Setting 2
R6 43.8 0.0 0.0 0.0 0.0 47.8 91.6
PoD-TPI 6.7 0.0 0.0 37.9 0.5 10.7 55.8
Setting 3
R6 48.1 0.0 0.0 0.0 0.0 143.9 192.0
PoD-TPI 9.6 0.0 0.0 22.8 1.8 3.9 38.1
Setting 4
R6 24.1 0.0 0.0 0.0 0.0 47.0 71.1
POD-TPI 14.4 0.0 0.0 43.2 0.5 13.2 71.3
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Figure S1: Scenario-specific PCS, PCA and POA for mTPI-2, R-TPI, TITE-CRM, TITE-BOIN
and PoD-TPI under Setting 1.
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Figure S2: Scenario-specific frequencies of inconsistent and risky decisions for mTPI-2, R-TPI,
TITE-CRM, TITE-BOIN and PoD-TPI under Setting 1.
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S4 Cure Rate Model
To construct a cure rate model, we introduce an additional notation Gi, such that Gi = 1 (or 0)
represents that patient i experiences DLT eventually (or never experiences DLT during his/her
lifetime). We model Gi with a Bernoulli distribution, Gi | Zi = d ∼ Bernoulli(ξd). It is easy to
see that ξd ≥ pd, as Yi = 1 always implies Gi = 1. We have Pr(Yi = 1 | Gi = 1, Zi = d) = pd/ξd.
Still, we assume a piecewise uniform distribution for [Ti | Yi = 1, Gi = 1, Zi = d] on the interval
(0, τ ]. The conditional density of Ti is
fT |Y,G,Z(t | Yi = 1, Gi = 1, Zi = d,w) = wk · 1
hk − hk−1 , for hk−1 < t ≤ hk.
Next,
fT |Z(t | Zi = d, pd, ξd,w) =
∑
y∈{0,1}
∑
g∈{0,1}
[
fT |Y,G,Z(t | Yi = y,Gi = g, Zi = d,w)×
Pr(Yi = y | Gi = g, Zi = d, pd, ξd) Pr(Gi = g | Zi = d, ξd)
]
= wk · 1
hk − hk−1 ·
pd
ξd
· ξd + 0 + 0 + 0 = pd · wk · 1
hk − hk−1 , for hk−1 < t ≤ hk,
and
ST |Z(t | Zi = d, pd, ξd,w) = 1− pd
K∑
k=1
wkβ(t, k), for t ≤ τ.
We can see the cure rate model does not change anything in the likelihood (7), i.e., ξd’s do not
contribute to the likelihood. This is expected, as the data only provide information for ξd up to
pd (ξd ≥ pd). In other words, after patients have been followed for τ , we do not care whether
they experience DLT eventually. Nevertheless, the interpretations of fT |Z and ST |Z are slightly
different, as we have
∫ t
0
fT |Z(v | Zi = d, pd, ξd,w) dv ≤ ξd for any finite t.
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